# Quality of Recovery After Reversal With Neostigmine or Sugammadex.

> **NCT02909439** · PHASE4 · COMPLETED · sponsor: **Stony Brook University** · enrollment: 80 (actual)

## Conditions studied

- Incomplete Reversal of Neuromuscular Block

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT02909439
- **Lead sponsor:** Stony Brook University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-11-09
- **Final completion:** 2018-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02909439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02909439, "Quality of Recovery After Reversal With Neostigmine or Sugammadex.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02909439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*